Ann: Positive Phase II Data from Clinical Trial of R327 Gel, page-36

Oh dear. The irony and ignorance immediately at "let me dumb it down for you". Here's a clue. When you walk into social settings and talk to people you've never met repugnantly, and they punch you in the face, it is perhaps your approach - online platforms no different. Perhaps even worse when they show the sheer arrogant overreach, of your ignorant and rudely expressed opinion to everyone therein. Lets do that....

Contrary to your ignorant, ill-informed, and no doubt racists assumptions about Indonesian healthcare spend, despite Indonesia not having the per capita wealth/health spend of many nations, the government has made significant efforts on Indonesia's health expenditure in the last decades doubling from 2010 to 2018, etc, etc. In 2023 Indonesian health expenditure was reported at US$ 375.5 billion (according to the WHO - excuse me if I listen to them and not you). Public financing accounted for more than 50% (hint, hint, those poor masses you speak of, are somewhat served by an Indonesian government spending heavily on health and looking for affordable solutions to common medical conditions....are we following yet, a phase III trial to be done in collaboration with the Indonesian Govt.?).

I know, they are probably all just 'poor dark Muzzies' to you but just to give you an idea, Australian Govt. healthcare expenditure on health, aged care and sport in 2023-24 was $137.6 billion AUD (that would be around half of that the Indonesian Government spent in case you struggle with maths and exchange rates). Again, Australia as a whole, according to the Australian Institute of Health, spent around $250 billion AUD on health goods and services in 2022–23. Again Australian healthcare expenditure in total, is around half that of Indonesia, so you can fathom the market opportunity Indonesia represents to RCE (crudely twice the Aussie mkt in $$).

If you are going to go rudely adversarial with strangers, the risk is of course you rudely assume they are ignorant (I've an MBA and MFin to my name, but thanks for your wizened "investment truism"). Quite evidently you like to express your (rude and very poorly informed) opinion online, rather than doing a little basic intelligent research. Clearly you haven't the faintest idea of the reality of Indonesian healthcare expenditure, particularly the high government aspect of and actual monetary size that is actually double that of Australia - not surprisingly to anyone with a modicum of intelligence, given its tenfold larger population.

Indonesia is an excellent market opportunity for Recce in R327 Gel, as the figures show, contrary to your rude and baseless opinion - funnily enough why they are trialling there with the Indonesian Govt.